The current World Health Organisation (WHO) classification of renal tumours is based on characteristic histological features or specific molecular alterations. von Hippel-Lindau (VHL) alteration is the hallmark of clear cell renal cell carcinoma (RCC). After identification of the MiT translocation family of tumours, clear cell papillary renal cancer and others, the group of ccRCC with wild-type VHL is small. TCEB1 mutation combined with chromosome 8q loss is an emerging tumour entity with wild-type VHL. Inactivation of TCEB1 increases HIF stabilisation via the same mechanism as VHL inactivation. Importantly, recent molecular analyses suggest the existence of another 'VHL wild-type' evolutionary subtype of clear cell RCC in addition to TCEB1 mutated RCC and clear cell papillary renal cancer. These tumours are characterised by an aggressive behaviour, high tumour cell proliferation rate, elevated chromosomal instability and frequent presence of sarcomatoid differentiation. Future clinicopathological studies will have to provide data to determine whether TCEB1 tumours and clear cell RCC with wild-type VHL are separate tumour entities or represent variants of a clear cell RCC tumour family.
Introduction
Tumour classification is important for outcome prediction and treatment decisions. In the past, tumour classification was based mainly on morphological parameters assessed by light microscopy. The histological classification of renal tumours has developed over time, and refers to various characteristic features. Different renal tumour entities are named according to predominant cytoplasmic features and staining characteristics (clear cell and chromophobe RCC). The clear cytoplasm of clear cell renal cell carcinoma (ccRCC) is due to accumulation of glycogen and lipids that are dissolved by deparaffinising formalin-fixed paraffin-embedded (FFPE) sections using organic solvents. 1 Architectural features (papillary RCC), a combination of such features (clear cell papillary RCC), the anatomical location of the tumour (collecting duct RCC) or a correlation with background renal disease (acquired cystic disease-associated RCC) are also used for tumour classification. In recent years there has been a trend to refer to molecular alterations that are pathognomonic for RCC subtypes (e.g. MiT family translocation renal carcinomas, SDH-deficient renal cancer or HLRCC-associated RCC with specific FH mutations). Emerging renal cancer entities include ALK-rearrangement-associated RCC. Molecular findings coming from large sequencing efforts and novel genotype/phenotype correlations will have a dramatic impact on future classification systems.
The relevance of von Hippel-Lindau gene (VHL) alterations for sporadic ccRCC was identified after studies of families with VHL syndrome. The prevalence of VHL alterations in sporadic ccRCC has been reported to range from 56% to 91% (Table 1) . Some novel renal tumour entities of the 2016 WHO classification are also characterised by clear cytoplasm and show significant morphological overlap with ccRCC. 2 Therefore, translocation carcinomas, acquired cystic disease (ACD)-associated RCC and clear cell papillary RCC have certainly influenced the prevalence of VHL alterations in older series, as they would have been diagnosed as ccRCC. TCEB1 renal cancer is an emerging tumour entity. These tumours also have a characteristic clear cytoplasm. The aim of this review is to discuss the consequence of these new molecular findings for future renal tumour classifications.
The VHL gene in ccRCC
Among the several histological subtypes of renal cell carcinomas, clear cell renal carcinoma remain the most prevalent, making up 70% of all renal cancers. 2, 3 For decades, it has been well accepted that the majority of ccRCC are characterised by bi-allelic loss of the VHL tumour suppressor gene located on chromosome 3p25-26. 4, 5 However, VHL alterations are absent in other renal tumour subtypes, e.g. papillary RCC, clear cell papillary RCC, translocation carcinomas and chromophobe carcinomas. Patients suffering from the autosomal-dominant von HippelLindau syndrome, an inherited familial disorder, receive a single inactivated copy of the VHL gene. Due to the haplosufficient nature of VHL, those suffering from VHL syndrome demonstrate a one-hit model for tumorigenesis in which a single inactivation step is required for a tumour to form. 6, 7 In sporadic ccRCC, VHL inactivation follows the Knudson two-hit model for tumorigenesis where two active copies of VHL are sequentially altered. 7 Bi-allelic inactivation of VHL occurs via mutations, copy deletion and promotor hypermethylation (see Figure 1) . 5, [8] [9] [10] The VHL gene product, pVHL, is a multi-adaptor protein that binds more than 30 different binding partners. 11 pVHL is a key component of the E3 ubiquitin ligase complex and is essential for the oxygendependent ubiquitin-mediated proteolytic degradation of HIF-a. 12 The loss of function of pVHL in ccRCC leads to stabilisation of the HIF-a subunits which, in turn, enhances the transcription of HIF gene targets such as VEGF, PDGF, EPO, CA9 and CXCR4. These proteins are known to be important in metastatic processes. 13 pVHL also interacts with several effector proteins that regulate cellular processes, including microtubule stability, activation of p53, neuronal apoptosis, cellular senescence and aneuploidy, ubiquitination of RNA polymerase II and regulation of nuclear factor kappa B (NF-kB) activity. 11, 13 ccRCC beyond VHL It is becoming increasingly evident that other tumour suppressor genes alongside VHL on the 3p arm are also key for tumorigenesis and tumour evolution in ccRCC. The genes coding Polybromo-1 (PBRM1), BRCA1-associated protein-1 (BAP1) and Set domaincontaining 2 (SETD2) are all located adjacent to VHL on chromosome 3 and commonly lost along with VHL upon 3p arm deletion.
8 PBRM1 encodes for BAF180, a key component for the PBAF SWI/SNF chromatin remodelling complex associated with DNA damage repair, replication and cell proliferation. 14, 15 BAP1 codes for a nuclear deubiquitinase and plays a key role in histone modification, 16 and SETD2 encodes a histone H3K36 methyltransferase and is thought to maintain genome stability and coordinate DNA repair. 17 Several large-scale sequencing studies focusing on ccRCC have shown that, after VHL, these three genes are the most frequently mutated in ccRCC, making evident their importance in ccRCC development and progression. 8, 14, [18] [19] [20] PBRM1 mutations are present in approximately 40% of ccRCC, whereas BAP1 and SETD2 are found to be mutated in approximately 10% of ccRCC.
Reduced expression of PBRM1 has been associated previously with poorer prognosis 21 ; however, recently Miao et al. 22 have demonstrated an increased clinical benefit of immune checkpoint therapy in patients with inactivated PBRM1, as defined by the Response Evaluation Criteria In Solid Tumours (RECIST) guidelines. This indicates that PBRM1 loss induces changes resulting in an increased susceptibility to immunotherapy. 22 Univariate and multivariate analysis has shown that BAP1 mutation have been associated with reduced overall survival, which is not true for both PBRM1 and SETD2 mutations. 8, 20 Moreover, BAP1 mutations were found to be mutually exclusive with PBRM1 mutations while SETD2 mutations are not seen in the presence of BAP1 mutations, but are found either alone or in combination with PBRM1. The fact that the most frequently mutated genes after VHL play roles in chromatin remodelling and histone modifications highlight the importance of epigenetic regulation in ccRCC. Notably, the SWI/SNF family is largely implicated in ccRCC not only with the frequent PBRM1 mutations, but also with less frequent ARID1A, SMARCA2 and SMARCA4 mutations, which all form components of the SWI/SNF family. 20 In addition to these epigenetic regulators, many other gene mutations and somatic copy number aberrations (SCNA) have been associated with ccRCC. Alterations in PTEN, PI3Kca and mTOR are also prevalent in ccRCC, which are all key players in the PI3k-AKT-mTOR pathway regulating cell proliferation and HIF stabilisation. 8, 20, 23 With regard to SCNA in ccRCC, 5q gains are the second most frequent alterations following 3p deletions with the SQSTM1 gene, thought to be the pathogenic target for this gain. 24, 25 SCNA are common in ccRCC, with alterations in nearly all chromosomes being observed; however, loss of 14q and chromosome 9 have been specifically associated with a poorer prognosis in ccRCC. [26] [27] [28] Studies have shown that VHL inactivation alone is insufficient for tumorigenesis, 29 highlighting the importance of the SCNA and secondary driver genes for formation and progression of ccRCC. Turajlic et al. 18 further demonstrate the importance of these elements for the evolution of ccRCC. Following the identification of driver event ordering and mutual exclusivity from 1206 tumour regions from 101 patients, seven evolutionary subtypes of ccRCC were described. Five of the seven evolutionary subtypes included at least one of the secondary driver mutations along with VHL. The 'PBRM1 ? SETD2' subtype was defined by mutatons in PBRM1 followed by SETD2, the 'PBRM1 ? PI3k' subgroup was defined by PBRM1 mutations followed by alterations in the PI3K/AKT pathway, e.g. TSC1 and mTOR, the 'PBRM1 ? SCNA' subgroup was defined by mutations in PBRM1 followed by a driver SCNA event, the 'BAP1 driven' subgroup was defined by BAP1 as the single driver event with VHL, and finally the 'multiple clonal drivers' evolutionary subtype, which was defined by tumours in which two or more secondary driver genes where clonally mutated. 18 ccRCCs with wild-type VHL If MiT-family translocation RCC and clear cell papillary RCC are classified correctly, the vast majority of ccRCC is characterised by the inactivation of VHL. However, there remains a subset of ccRCC cases with active VHL considered wild-type VHL ( wt VHL) ccRCC. Most ccRCC studies have focused on the frequencies of VHL mutation and chromosome 3p loss to study ccRCC with inactivated VHL. Therefore, details with regard to the molecular background of wt VHL ccRCC cases are limited. Several groups have stratified their data by VHL mutation types, and found that missense mutations may exert different effects on both pVHL stability and binding capability. 11, 30, 31 All three methods of inactivation -mutation, 3p loss and promotor hypermethylation -have been the focus of just a few studies. However, data concerning the number of ccRCC retaining one or two wt VHL alleles were indirectly described in several of these studies, which are listed in detail in Table 1 and summarised in Figure 1 .
That said, Dagher et al. made the first attempt to isolate and compare active VHL ccRCC to inactivated VHL ccRCC. From their retrospective analysis of 98 patients, Dagher et al. identified 11 patients in whom both VHL copies were active and a further 22 samples in whom only a single copy of VHL was active, i.e. a single hit of VHL inactivation. Active VHL ccRCC tumours in which at least a single active copy of VHL was remaining showed a more aggressive profile than those with inactivated VHL. The active VHL tumours had higher nuclear differentiation grades and were significantly associated with sarcomatoid components, dense lymphocyte infiltration, metastasis and an increased expression of intratumoral VEGF. ccRCC cases with two active copies of VHL ('truly' wt VHL ccRCC) were also shown to also have significantly lower survival compared to those with a single or bi-allelic inactivation of VHL. 32 The aggressive nature of wt VHL ccRCC was further confirmed in another study by Turajlic et al., 33 in which they examined the routes and timing of ccRCC tumour metastasis. The result was the division of their cohort, made up of 575 primary and 335 metastatic biopsies across 100 patients, into two groups: cases with rapid progression and those with attenuated progression. They found that the rapid progression group was enriched with wt VHL tumours, associated with lower intratumor heterogeneity and increased genomic instability. 33 With the use of immunohistochemistry, active VHL ccRCC tumours have also been associated with programmed death ligand 1 (PD-L1) expression, particularly those with two active copies of VHL.
34 PD-L1 is a transmembrane protein which has been shown to be expressed in a large number of cancers, including melanomas, breast and lung cancers. PD-L1 binds to its receptor programmed cell death protein 1 (PD-1) present on the cell surface of T cells, attenuating their anti-tumour response and thereby promoting cancer survival and progression. 35 PD-L1 is a key target for cancer immunotherapy; preventing the interaction of PD-L1 with PD-1 would increase tumour recognition and increase the immune response against the cancerous cells. As traditional broad cancer treatments are ineffective against renal carcinomas, targeted therapies are being developed for the treatment of ccRCC. 36 Due to the strong associations of PD-L1 expression with wt VHL ccRCC, Kammerer-Jacquet et al. 34 suggest that these cases would benefit from PD-1/PD-L1 targeted therapies.
Distinguishing 'true' from 'non-true' wt VHL clear cell renal cell carcinoma by histology
Although no molecular characterisation of 'true' ccRCC with wt VHL has been carried out to date, there have been attempts to distinguish histologically between ccRCC and wt VHL renal carcinomas. The histology of VHL mutated ccRCC can be seen in Figure 2A . Clear cell papillary renal cell carcinomas (CCPRCC) and renal angiomyoadenomatous tumours (RAT) are described as two relatively novel renal carcinoma subgroups. These tumours have markedly similar histologies, with clear cytoplasm within their epithelial cells with low grade-nuclei ( Figure 2B ). CCPRCC and RAT have also been shown to have similar morphological and immunohistochemical properties to ccRCC, but are not associated with 3p loss or VHL mutation, i.e. are wt VHL. [37] [38] [39] In spite of this, a few cases thought to be CCPRCC have shown VHL mutations and it is not clear if these are truly CCPRCC or ccRCC. It is thought that these subtypes of RCC are not rare, and cases are present around the world which are simply not recognised. CCPRCC is thought to have a prevalence rate of approximately 1-4% and that approximately 6% of low-grade ccRCC are, in fact, CCPRCC. 40, 41 Furthermore, following immunohistochemical and fluorescence in-situ hybridisation (FISH) analysis, few RAT cases have been reclassified to translocation RCC (tRCC). tRCC are characterised by chromosomal translocations of Xp11.2, the location of TFE3 and, less frequently, 6p21, the location of TFEB, 39 but are not associated with VHL inactivation. It may be that a proportion of ccRCC with wt VHL are CCPRCCs, RAT or tRCC. Molecular characterisation of the Cancer Genome Atlas ccRCC cases showed that five cases, which were all wt VHL tumours, had SFPQ-TFE3 fusions specific to tRCCs with a clear cell histology. 8 As there is a clear genetic marker for tRCCs, identification and reclassification of wt VHL ccRCC to tRCC would be possible. However, due to the similarities between RAT, CCPRCC and wt VHL ccRCC morphologies, and considering that RAT and CCPRCC have yet to be identified as molecularly distinguishable subgroups of RCC, classification of wt VHL ccRCC to CCPRCC and RAT would be difficult. (See section 'TCEB1 RCC and CCPRCC/RAT are separate entities' for more information concerning RAT and CCPRCC.)
TCEB1-deficient wt VHL ccRCC
Sato et al. were the first to identify inactivation of the TCEB1 gene in a fraction of wt VHL ccRCC cases.
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TCEB1 codes for Elongin C that, like the VHL protein, is part of the E3 ubiquitin ligase complex. Similar to VHL inactivation by mutation and chromosome 3p loss in ccRCC, TCEB1 mutations are accompanied with a chromosome 8q loss resulting in complete inactivation of TCEB1. No differences were found between the clinicopathological properties of cases in which TCEB1 was inactivated and those with VHL inactivation. Examination of HIF-a expression via immunohistochemistry showed elevated levels of HIFa within TCEB1-inactivated ccRCC compared to those without VHL or TCEB1 mutations and normal kidney tissue. These results support the idea that inactivation of TCEB1 is thought to increase HIF stabilisation via the same mechanism as VHL inactivation. Using the Sato et al. 20 cohort, along with ccRCC cases from the TCGA, Hakimi et al. 42 carried a more detailed analysis of the TCEB1 inactivated ccRCC. The morphology of these tumours was distinct, but there were no 'specific' histological features. Following extensive molecular analysis of 11 TCEB1 inactivated tumours, it was found that mutations exclusively affected two residues: Y79C/S/F/N or A100P, both essential for the interaction between Elongin C and pVHL. 42 All 11 tumours were wild-type for VHL and had no 3p loss with no alterations affecting the function of PBRM1, SETD2 or BAP1. Given a similar morphology of ccRCC and TCEB1 tumours, together with the fact that inactivation of TCEB1 increases HIF stabilisation via the same mechanism as VHL inactivation, one could argue that TCEB1 tumours can be regarded as part of a spectrum of ccRCC. A tumour with chromosome 8q deletion suggestive for TCEB1 alteration is shown in Figure 2C .
TCEB1 RCC and CCPRCC/RAT are separate entities
The 2016 WHO classification has not designated TCEB1 RCC as its own tumour entity. For the time being they are regarded as an emerging or provisional entity, following the controversy at the 2015 WHO consensus conference in Z€ urich regarding the overlap of these tumours with the group of RCC associated with prominent (angio)leiomyomatous stroma. Two groups have provided seminal work characterising RCC associated with prominent (angio)leimyomatous stroma or with a clear cell papillary RCC-like morphology. The Ondrej Hes et al. group has pointed out that a prominent (angio)leimyomatous stroma is not a feature of a specific entity, but can be seen in otherwise typical ccRCC and even in papillary RCC. [43] [44] [45] RAT is an indolent low-grade neoplasm with overlapping histological features to clear cell papillary RCC (CCPRCC). RAT and CCPRCC are discussed as two separate entities or as two ends of a spectrum within one tumour family, 44, 46 similar to the mixed epithelial and stroma tumour family encompassing tumours ranging from predominantly cystic tumours (adult cystic nephromas) to more solid variants (MEST). There are no exact criteria for distinguishing RAT and CCPRCC. Whereas RAT exhibits a voluminous stromal component, CCPRCC have a less prominent smooth muscle stroma. RAT and CCPRCC have an almost equal immunophenotype and molecular background. Both are characterised by strong and diffuse CK7 positivity and lack of VHL gene abnormalities. 44 Before the acceptance of CCPRCC as a unique entity, CK7 immunoreactivity in ccRCC has been regarded as a favourable prognostic feature or as a specific subset of ccRCC. 47, 48 Therefore, it is reasonable to argue that RAT and CCPRCC are two related tumours characterised by the absence of VHL alterations. This is consistent with molecular results from Williamson et al. 49, 50 Williamson's group identified VHL alterations in ccRCC with borderline features of CCPRCC as well as in VHL-related ccRCC with features of CCPRCC. Williamson et al. argue that there remain tumours with CCPRCC-like morphology, more diffuse CK7 staining and VHL alterations. Such tumours should be regarded as a manifestation of ccRCC and potentially represent a more aggressive neoplasm than RAT/CCPRCC. For diagnostic purposes, a diagnostic algorithm using CK7, TFE3, MET, Parafibromin and hKIM-1 has been proposed. 39, 43 In selected cases, it is necessary to perform molecular analysis to identify VHL alterations to separate ccRCC from RAT/CCPRCC. This is clinically relevant, because RAT/CCPRCC have an indolent behaviour in almost all cases.
Very recently, Petersson et al. 45 studied a cohort with prominent smooth-muscle stroma by next-generation sequencing (NGS). They identified a group of tumours with an epithelial component indistinguishable from conventional ccRCC and distinct from CCPRCC. These tumours lack both aberrations related to the function of the VHL gene and hot-spot mutations in TCEB1. This is consistent with findings by Favazza et al., who reviewed whole-slide images of 418 tumours in the published TCGA ccRCC database 51 ; 93% had VHL alterations. The remaining wild-type VHL group contained translocation renal cell carcinomas, TCEB1 mutant RCC, papillary RCC and CCPRCC (n = 27). Six cases had ccRCC-associated gene alterations (PBRM1, SMARCA4, BAP1, SETD2), leaving 11 specimens, including two highgrade or sarcomatoid RCC and two cases with prominent fibromuscular stroma (not TCEB1 mutant). These two tumours may fall into the category of RCCs with leiomyomatous stroma and wt VHL, described by Petersson et al.
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Non-TCEB1-deficient wt VHL ccRCC Although TCEB1 inactivation is able to account for a fraction of wt VHL ccRCC they are extremely rare, with approximately 12 cases reported worldwide. 18, 20, 42 Vitally, these do not account for all wt VHL ccRCC cases, still leaving the root cause for many wt VHL ccRCC cases unknown. Referring back to the seven evolutionary subtypes of ccRCC identified by Turajlic et al., 18 one of the identified evolutionary trajectories was 'VHL wild-type'. Cases within this group were defined by active VHL within their tumours, i.e. no bi-allelic inactivation of VHL. The one case with TCEB1-inactivated ccRCC was not included within this group. The VHL wild-type group was associated with elevated cell proliferation marker and higher genomic instability. The driver phylogenetic trees for this group of patients showed various alterations as initiators for tumorigenesis, such as SCNA, SETD2 mutations and PTEN mutations. Markedly, three wild-type VHL cases had evolutionary pathways initiated by PBRM1 followed by either SCNA (two cases) or SETD2 alterations (one case). Additionally, another wt VHL case had a driver phylogenetic tree similar to that of the 'multiple clonal drivers' subgroup in that alterations within several key driver genes, e.g. PBRM1, BAP1 and SETD2, were the route cause for tumorigenesis. This suggests that in the absence of VHL alteration it may be possible for alterations in PBRM1 alone or in combination with specific alterations within other known key driver genes to initiate ccRCC tumorigenesis. 18 
Conclusion
In recent years, significant advances have been made in the molecular characterisation of renal tumours with clear cytoplasm. A subset of tumours with clear cell histology and wild-type VHL can now be reclassified as other entities, including translocation RCC and the CCPRCC/RAT tumour family. Clear cell papillary RCC is defined as an own tumour entity with a characteristic morphology. TCEB1 inactivation is able to account for another fraction of wt VHL ccRCC. RCC with mutations in the TCEB1 gene represent a distinct genomic subtype of RCC. Given its 'non-specific' clear cell morphology, the diagnosis requires genomic testing. Importantly, inactivation of TCEB1 increases HIF stabilisation via the same mechanism as VHL inactivation. Therefore, renal cancers with inactive VHL and TCEB1 mutation-associated RCC could represent variants of ccRCC with different initiating molecular events. According to this literature review, it is evident that a small group of RCC with clear cell morphology and wild-type VHL (true wt VHL ccRCC) exists in addition to TCEB1 mutated RCC and CCPRCC/RAT. ccRCC with active VHL ( wt VHL) develop via evolutionary pathways initiated by PBRM1 and SETD2 alterations or they fall into the 'multiple clonal drivers' subgroup. There is evidence in the literature that wt VHL ccRCC have an aggressive behaviour. Future classification systems will consequently use the molecular background to define tumour entities. It has to be decided, in a future classification of RCC, if a diagnosis of ccRCC with wt VHL can be made. Currently, such tumours should be formally diagnosed as 'unclassified RCC'.
